Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc demonstrated robust financial performance with a remarkable 98% year-over-year revenue growth in the third quarter, achieving $13.1 million in total revenue. The company has successfully increased its surgeon customer base by over 70% year-over-year, resulting in enhanced utilization rates and solid productivity metrics of 1.9 units per surgeon. Additionally, Carlsmed's gross margin of 75.9% surpassed expectations due to decreased manufacturing costs and lower inventory expenses, positioning the company favorably within the expanding $13.4 billion lumbar fusion market and the anticipated cervical market expansion.

Carlsmed Inc. faces a challenging outlook primarily due to projected revenue for its cervical segment, estimated at $2.9 million for FY26, falling short of prior expectations and highlighting concerns over market penetration for its Aprevo technology. Several factors contribute to this negative outlook, including the potential for slower adoption rates among surgeons, lower growth rates in the overall spine market, and faster-than-anticipated degradation of average selling prices (ASP). Additionally, the company's operating expenses may rise beyond initial projections, compounded by competitive pressure from larger firms and possible adverse changes in reimbursement policies impacting hospital economics and pricing.